Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.
CV Sciences, Inc. reports financial results and operating updates for a consumer wellness business focused on hemp extracts, CBD products and natural wellness ingredients. News commonly covers revenue trends, gross margin, operating expense reductions, adjusted EBITDA, cash flow objectives and balance-sheet actions such as secured note amendments and convertible debt features.
Company updates also include product launches across +PlusCBD, +PlusHLTH, Ignite and Empowr, including CBD gummies, pet products, cannabinoid-free supplements and plant-based nutrition formulas. Recurring coverage also addresses the evolving regulatory environment for hemp-derived CBD and the company’s efforts to broaden its wellness product portfolio.
CV Sciences (CVSI) welcomed new U.S. federal legislation that delays implementation of tightened hemp restrictions from November 12, 2026 to December 11, 2026.
The law, signed on September 1 after passing the House 370-48 and the Senate 90-6, preserves continued access to qualifying naturally derived hemp products during the extension period. CV Sciences views the delay as an opportunity for Congress and the Administration to create a clear, science-based regulatory framework for hemp-derived cannabinoid products, including standards for manufacturing, testing, labeling and marketing. The company plans to engage with policymakers and industry stakeholders as long-term rules are developed.
CV Sciences (OTCQB:CVSI) reported second quarter 2026 revenue of $3.0 million, down 17.5% from $3.6 million a year earlier and slightly below $3.2 million in Q1 2026. Gross margin was 48.6%, versus 50.9% in Q2 2025 and 48.9% in Q1 2026.
Operating expenses fell 11.3% year over year to $1.7 million, contributing to an operating loss of $0.3 million compared with a $0.1 million loss in Q2 2025. Net loss widened to $0.8 million from $0.3 million, while adjusted EBITDA was a $0.1 million loss versus positive $0.1 million last year. Cash at June 30, 2026 was $0.27 million.
The company said 44% of Q2 2026 net revenue came from 52 new products launched since January 1, 2023, and it expanded its +PlusHLTH™ portfolio and launched PlusHLTH.com. According to CV Sciences, a recent U.S. Senate Continuing Resolution delays restrictive hemp-derived cannabinoid provisions, providing additional time to shape longer-term regulation.
CV Sciences (OTCQB:CVSI) announced the launch of PlusHLTH.com on August 11, 2026, a dedicated direct-to-consumer platform for its +PlusHLTH™ non-cannabinoid wellness line. The site focuses on healthy aging, performance, and everyday health, complementing PlusCBDOil.com, which remains centered on hemp-derived CBD products.
Built around the company’s Health Intelligence approach, PlusHLTH.com combines e-commerce with educational content to help consumers understand changing health needs and explore targeted, science-backed solutions. It will be the primary digital home for +PlusHLTH™ supplements, the Empowr plant-based protein with creatine, and future product innovations.
CV Sciences (OTCQB:CVSI) will release its financial results for the second quarter ended June 30, 2026, after the market close on Thursday, August 13, 2026. Management will host a conference call with investors at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day.
The live webcast will be accessible via the Investor Relations section of the company’s website and a dedicated webcast link, with an archive available for about 30 days. Investors may also join by phone using U.S. dial-in (877) 407-0784 or international (201) 689-8560. A telephone replay will be available until August 20, 2026 using replay numbers (844) 512-2921 (U.S.) or (412) 317-6671 (international) with confirmation code 13761707.
CV Sciences (OTCQB:CVSI) expanded its cannabinoid-free +PlusHLTH supplement line, built on its Health Intelligence approach to personalized wellness. New formulations target cardiovascular health, brain performance, cellular energy, muscle and nerve balance, mobility, and appetite control, complementing the existing +PlusCBD brand and broadening CV Sciences' presence in the health and wellness market.
CV Sciences (OTCQB:CVSI) reported Q1 2026 revenue of $3.2 million, down 11.4% year over year, with units sold down 12.2%. Gross margin was 48.9%. Operating loss was $0.3 million and adjusted EBITDA loss $0.1 million. Operating expenses fell 13.3% to $1.9 million, cash ended at $0.3 million. The company completed a debt restructuring, launched its EMPOWR wellness product, and noted that 43% of Q1 2026 net revenue came from 45 products launched since January 1, 2023.
CV Sciences (OTCQB:CVSI) will release first quarter 2026 financial results for the period ended March 31, 2026, after the market close on Thursday, May 14, 2026.
The company will host a conference call at 1:30 p.m. PT (4:30 p.m. ET), with a live webcast and 30-day archive.
CV Sciences (OTCQB:CVSI) reported fiscal 2025 revenue of $13.8M, down 12.2% from 2024, with year-end cash of $0.3M. Gross margin improved to 49.0% from 45.6%, operating expenses fell 17.2% to $7.7M, and adjusted EBITDA narrowed to a $0.3M loss, with positive adjusted EBITDA of $0.1M in Q4. The company completed a debt restructuring (Q1 2026) and launched new products including Ignite (Q3 2025) and EMPOWR (Q1 2026).
Management emphasized margin expansion, cost cuts, and targeted M&A to pursue sustainable profitability and cash flow in 2026.
CV Sciences (OTCQB:CVSI) will release year‑end and fourth quarter 2025 results after market close on March 26, 2026 and will host a conference call the same day at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast and archived replay will be available via the company's Investor Relations site.
Telephone participation and a replay are provided, with the replay available through April 2, 2026 using confirmation code 13759006.
CV Sciences (OTCQB:CVSI) announced a debt restructuring that adds a conversion feature allowing outstanding notes to be converted into common shares at a fixed price of $0.06 per share. The company says this change aims to strengthen the balance sheet and increase financial flexibility to support growth and product expansion, including the new Empowr plant-based protein and creatine formula under the +PlusHLTH™ line.